No therapeutic response adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From October 2004 to June 2016, FDA received 12,198 adverse event reports that record the MedDRA preferred term No therapeutic response. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 0 reports in the 12 months to June 2026 and 0 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 1 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 129 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term No therapeutic response name as a suspect product, in order of name
Drug	Class	Reports with this term
Actemra	Interleukin-6 receptor antagonist	28
Afinitor	Kinase inhibitor	29
Amlodipine	Calcium channel blocker	37
Ampyra	Potassium channel blocker	33
Aranesp	Erythropoiesis-stimulating agent	38
Aspirin	Nonsteroidal anti-inflammatory drug	132
Avastin	Vascular endothelial growth factor inhibitor	55
Azacitidine	Nucleoside metabolic inhibitor	47
Azathioprine	Purine antimetabolite	31
Baclofen	gamma-Aminobutyric acid-ergic agonist	450
Baclofen Intrathecal		30
Bevacizumab	Vascular endothelial growth factor inhibitor	63
Bupivacaine	Amide local anesthetic	75
Carbamazepine	Mood stabilizer	39
Carboplatin	Platinum-based drug	74
Ciprofloxacin	Fluoroquinolone antibacterial	44
Cisplatin	Platinum-based drug	48
Citalopram hydrobromide	Serotonin reuptake inhibitor	31
Claritin		25
Clonazepam	Benzodiazepine	42
Clonidine	Central alpha-2 adrenergic agonist	63
Clozapine	Atypical antipsychotic	25
Compounded Baclofen		43
Copegus		65
Cyclophosphamide	Alkylating drug	148
Cyclosporine	Calcineurin inhibitor immunosuppressant	52
Cymbalta	Serotonin and norepinephrine reuptake inhibitor	41
Cytarabine	Nucleoside metabolic inhibitor	122
Daunorubicin hydrochloride	Anthracycline topoisomerase inhibitor	25
Dexamethasone	Corticosteroid	129
Diazepam	Benzodiazepine	47
Digoxin	Cardiac glycoside	29
Dilaudid	Opioid agonist	80
Docetaxel	Microtubule inhibitor	31
Doxorubicin	Anthracycline topoisomerase inhibitor	28
Doxorubicin hydrochloride	Anthracycline topoisomerase inhibitor	30
Enbrel	Tumor necrosis factor blocker	1,084
Etoposide	Topoisomerase inhibitor	82
Fentanyl	Opioid agonist	70
Fludarabine	Nucleoside metabolic inhibitor	27
Fluorouracil	Nucleoside metabolic inhibitor	54
Fluoxetine	Serotonin reuptake inhibitor	28
Fosamax	Bisphosphonate	27
Furosemide	Loop diuretic	36
Gabapentin	Anti-epileptic agent	64
Gammagard		44
GAMMAGARD Liquid	Human immunoglobulin G	84
Gleevec	Kinase inhibitor	75
Glivec		161
Heparin		34
Herceptin	HER2/neu receptor antagonist	44
Humira		290
Ibuprofen	Nonsteroidal anti-inflammatory drug	40
Imatinib	Kinase inhibitor	26
Incivek		50
Jetrea		117
Lamotrigine	Anti-epileptic agent	49
Letairis	Endothelin receptor antagonist	216
Levaquin		64
Levetiracetam		49
Lioresal (baclofen)	gamma-Aminobutyric acid-ergic agonist	347
Lioresal Intrathecal		25
Lioresal Intrathecal 2000 Mcg/Ml		37
Lipitor	HMG-CoA reductase inhibitor	29
Lisinopril	Angiotensin converting enzyme inhibitor	66
Lorazepam	Benzodiazepine	47
Lucentis	Vascular endothelial growth factor inhibitor	31
Lyrica		37
Macitentan	Endothelin receptor antagonist	30
Mekinist	Kinase inhibitor	66
Methotrexate	Folate analog metabolic inhibitor	179
Methylprednisolone	Corticosteroid	52
MiraLAX	Osmotic laxative	26
Morphine	Opioid agonist	87
Mycophenolate mofetil	Antimetabolite immunosuppressant	43
Neulasta	Leukocyte growth factor	37
Nplate	Thrombopoietin receptor agonist	42
Olanzapine	Atypical antipsychotic	48
Omeprazole	Proton pump inhibitor	45
Opsumit	Endothelin receptor antagonist	72
Otezla	Phosphodiesterase 4 inhibitor	142
Oxaliplatin	Platinum-based drug	32
Oxycodone	Opioid agonist	26
Paclitaxel	Microtubule inhibitor	32
Pantoprazole	Proton pump inhibitor	30
Peg-Intron		65
Pegasys	Interferon alpha	302
Pegintron		73
Phenytoin	Anti-epileptic agent	25
Pomalyst	Thalidomide analog	48
Prednisolone	Corticosteroid	100
Prednisone	Corticosteroid	125
Prograf	Calcineurin inhibitor immunosuppressant	52
Prolia	RANK ligand inhibitor	26
Propofol	General anesthetic	36
Quetiapine	Atypical antipsychotic	27
Rebetol		109
Rebif	Interferon beta	75
Remicade	Tumor necrosis factor blocker	38
Revlimid	Thalidomide analog	511
Ribasphere		35
Ribavirin	Nucleoside analog antiviral	281
Risperidone	Atypical antipsychotic	39
Rituxan	CD20-directed cytolytic antibody	47
Rituximab	CD20-directed cytolytic antibody	86
Sertraline	Serotonin reuptake inhibitor	31
Simvastatin	HMG-CoA reductase inhibitor	43
Tacrolimus	Calcineurin inhibitor immunosuppressant	47
Tafinlar	Kinase inhibitor	74
Tarceva		30
Tasigna	Kinase inhibitor	26
Telaprevir		66
Thalidomide		46
Thalomid		53
Thymoglobulin	Immunoglobulin G	25
Topiramate		33
Tracleer	Endothelin receptor antagonist	121
Tysabri	Integrin receptor antagonist	38
Valchlor	Alkylating drug	34
Valproic acid	Anti-epileptic agent	28
Vancomycin	Glycopeptide antibacterial	40
Velcade	Proteasome inhibitor	63
Ventavis		49
Victrelis		75
Vidaza	Nucleoside metabolic inhibitor	112
Vincristine		59
Vincristine sulfate	Vinca alkaloid	56
Xeloda	Nucleoside metabolic inhibitor	31
Xolair	Anti-IgE	36

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 50 pharmacologic classes with 50 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term No therapeutic response name, in order of name
Class	Reports with this term
Alkylating drug	266
Amide local anesthetic	113
Aminoketone	62
Angiotensin converting enzyme inhibitor	89
Anthracycline topoisomerase inhibitor	94
Anti-epileptic agent	227
Antimetabolite immunosuppressant	58
Atypical antipsychotic	229
Benzodiazepine	225
beta-Adrenergic blocker	88
Biguanide	50
Bisphosphonate	69
Calcineurin inhibitor immunosuppressant	156
Calcium channel blocker	56
CD20-directed cytolytic antibody	133
Central alpha-2 adrenergic agonist	91
Corticosteroid	461
Endothelin receptor antagonist	449
Erythropoiesis-stimulating agent	76
Fluoroquinolone antibacterial	58
Folate analog metabolic inhibitor	192
gamma-Aminobutyric acid-ergic agonist	806
HER2/neu receptor antagonist	60
HMG-CoA reductase inhibitor	109
Human immunoglobulin G	93
Interferon alpha	321
Interferon beta	96
Kinase inhibitor	402
Leukocyte growth factor	60
Loop diuretic	59
Microtubule inhibitor	69
Mood stabilizer	68
Nonsteroidal anti-inflammatory drug	235
Nucleoside analog antiviral	281
Nucleoside metabolic inhibitor	473
Opioid agonist	379
Osmotic laxative	77
Phosphodiesterase 4 inhibitor	142
Platinum-based drug	154
Prostacycline vasodilator	75
Proteasome inhibitor	79
Proton pump inhibitor	146
Serotonin and norepinephrine reuptake inhibitor	90
Serotonin reuptake inhibitor	230
Thalidomide analog	568
Thrombopoietin receptor agonist	58
Topoisomerase inhibitor	101
Tumor necrosis factor blocker	1,189
Vascular endothelial growth factor inhibitor	158
Vinca alkaloid	65

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record No therapeutic response, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record No therapeutic response
Age	Reports	Share
Under 2	128	1%
2 to 11	272	2.2%
12 to 17	240	2%
18 to 44	1,855	15.2%
45 to 64	3,417	28%
65 to 74	1,320	10.8%
75 and over	941	7.7%
Age not given	4,025	33%

Sex of the patient in the reports that record No therapeutic response
Sex	Reports	Share
Female	6,206	50.9%
Male	4,982	40.8%
Unknown or not given	1,010	8.3%

Age and sex are as the report gives them. 71.9% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. No therapeutic response: adverse event reports that record this term. https://reportedreactions.com/reaction/no-therapeutic-response/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 1 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 1 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Oct 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does No therapeutic response mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page